| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
mPEG-DSPE does not have a specific biological receptor target. It functions as a lipid excipient that provides steric stabilization to liposomes and nanoparticles, reducing opsonization and prolonging circulation time.
|
|---|---|
| ln Vitro |
In vitro, mPEG-DSPE is used in the formation of stealth liposomes or micelles. The PEGylation of phospholipids significantly improves the stability of encapsulated drugs and can be used for targeted drug delivery by modifying surfaces with targeting ligands. It has strong self-assembly capabilities, forming uniform aggregates such as micelles in water, with a low critical micelle concentration (CMC).
|
| ln Vivo |
In vivo, mPEG-DSPE is used to formulate long-circulating liposomes. The PEG component improves blood circulation time and stability for encapsulated drugs. mPEG-DSPE-containing liposomes are used in drug delivery, gene transfection, and vaccine delivery. It has been shown to inhibit the growth of cancer cells in vivo.
|
| Enzyme Assay |
In vitro liposome formation with mPEG-DSPE involves dissolving the lipid with other phospholipids in organic solvent, drying to form a lipid film, and hydrating with aqueous buffer. The resulting liposomes are extruded to achieve uniform size. The PEG coating provides steric stabilization and reduces liposome aggregation.
|
| Cell Assay |
Cellular uptake studies of mPEG-DSPE-containing liposomes are performed using various cell lines. The steric stabilization provided by the PEG coating reduces non-specific cellular uptake while prolonging circulation. Liposomes encapsulating fluorescent markers or therapeutic agents are added to cell cultures, and uptake is quantified.
|
| Animal Protocol |
In vivo studies typically involve intravenous administration of mPEG-DSPE-containing liposomal formulations in rodent models. Pharmacokinetic parameters such as circulation half-life, tissue distribution, and therapeutic efficacy are evaluated. mPEG-DSPE is used in preclinical drug delivery research for oncology and infectious diseases.
|
| ADME/Pharmacokinetics |
mPEG-DSPE significantly improves the blood circulation time and stability of encapsulated drugs. The PEG component reduces opsonization and clearance by the mononuclear phagocyte system. Pharmacokinetic properties depend on the formulation and PEG molecular weight (MW 2000).
|
| Toxicity/Toxicokinetics |
mPEG-DSPE is generally considered biocompatible and is used in pharmaceutical formulations. The PEGylated phospholipid has been used in FDA-approved drug delivery systems. Standard safety precautions for handling lipids should be followed. No significant toxicity has been reported.
|
| References |
[1]. Rathore SS, et al. Effect of surface charge and density of distearylphosphatidylethanolamine-mPEG-2000 (DSPE-mPEG-2000) on the cytotoxicity of liposome-entrapped ricin: effect of lysosomotropic agents. Int J Pharm. 2008;350(1-2):79-94.;Hasan GM, et al. Inhibition of the Growth of Plasmodium falciparum in Culture by Stearylamine-Phosphatidylcholine Liposomes. J Parasitol Res. 2011;2011:120462.
|
| Additional Infomation |
mPEG-DSPE (MW 2000) is a PEGylated phospholipid that couples a hydrophobic distearoyl tail with a hydrophilic PEG chain. It is used in the formation of stealth liposomes or micelles and can be used for targeted drug delivery and drug solubility enhancement. The compound is widely used in liposome and nanoparticle synthesis. It is commonly used to modify the surface of liposomes to control surface properties, improve biocompatibility, and regulate drug release behavior.
|
| Molecular Formula |
C45H87NO11P-.NA+
|
|---|---|
| Molecular Weight |
2000(Average)
|
| Exact Mass |
875.661
|
| CAS # |
147867-65-0
|
| Related CAS # |
mPEG-DSPE (MW 2000) (sodium)
|
| PubChem CID |
86278269
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
857.5±65.0 °C at 760 mmHg
|
| Flash Point |
472.4±34.3 °C
|
| Vapour Pressure |
0.0±3.2 mmHg at 25°C
|
| Index of Refraction |
1.467
|
| LogP |
15.72
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
48
|
| Heavy Atom Count |
59
|
| Complexity |
994
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[C@H](COP(OCCNC(OCCOC)=O)(=O)[O-])(COC(CCCCCCCCCCCCCCCCC)=O)OC(CCCCCCCCCCCCCCCCC)=O.[Na+]
|
| InChi Key |
SRLOHQKOADWDBV-NRONOFSHSA-M
|
| InChi Code |
InChI=1S/C45H88NO11P.Na/c1-4-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-43(47)54-40-42(41-56-58(50,51)55-37-36-46-45(49)53-39-38-52-3)57-44(48)35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-5-2;/h42H,4-41H2,1-3H3,(H,46,49)(H,50,51);/q;+1/p-1/t42-;/m1./s1
|
| Chemical Name |
sodium;[(2R)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
